# Medi-Tate

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/medi-tate

- Industry: Medical Devices & Equipment
- Headquarters: Hadera, Israel
- Website: www.medi-tate.com
- Total disclosed funding: $2M
- Latest round: Series A (May 5, 2015)
- Investors on record: 1

## About

Medi-Tate Ltd., based in Israel, specializes in developing innovative medical devices, particularly focusing on solutions for urological conditions, including the iTind™ procedure for benign prostatic hyperplasia.Founded in 2007 and headquartered in Hadera, Israel, Medi-Tate Ltd. develops medical devices aimed at treating urological issues. The company was acquired in February 2021 by Olympus Corporation from Xenia Venture Capital and Laborie, Inc. for USD 300 mn. Prior to this, it had closed five deals and raised a total of USD 4 mn. The recent acquisition marked a significant pivot in Medi-Tate's operational strategy under Olympus's global reach.Medi-Tate Ltd. is recognized for the iTind™ procedure, which is a minimally invasive treatment for benign prostatic hyperplasia (BPH). This procedure utilizes a temporary implant that is removed after 5 to 7 days, facilitating rapid symptom relief while preserving sexual and urinary function. The primary customers for these solutions are urologists and hospitals across markets in the United States and Europe.Medi-Tate Ltd.'s revenue model is based on the sales of its medical devices, particularly the iTind™ procedure, through B2B transactions with healthcare providers. Urologists and medical institutions purchase the implants for patient treatments, integrating the iTind procedure into their practices and charging for the service as part of their offerings, thus aligning pricing with the value provided to patients.Following the acquisition in February 2021, Medi-Tate Ltd. aims to leverage the resources of Olympus Corporation to enhance its product development and market presence. The company anticipates expanding the reach of the iTind™ procedure into new geographic markets, particularly targeting additional European regions and increasing its footprint in the United States. The funding from the recent acquisition will support these growth initiatives and further advancements in product design.

## Funding rounds

- Series A, May 5, 2015, $2M — Xenia Venture Capital

## Investors

- Xenia Venture Capital (https://capitalatlas.ai/funds/xenia-venture-capital) — Series A